Results of brexucabtagene-autoleucel for patients with relapsed/refractory Mantle Cell Lymphoma in the routine setting in Germany and Switzerland

Bone Marrow Transplantation 2026 Open access

Read full text
Authors: Linda Simon, Vladan Vucinic, Kai Rejeski, Maria‐Luisa Schubert, Enver Aydilek, Eva Wagner-Drouet, O. Penack, Malte von Bonin, Bastian von Tresckow, Marcel Teichert, Reinhard Marks, Christiane Pott
+16 more Martin Fehr, Corinna Leng, Roland Schroers, Christian Koenecke, Johannes Duell, S. Stilgenbauer, F. M. Mueller, Judith S. Hecker, Uta Brunnberg, Nicolaus Kroeger, Kai Kronfeld, Matthias Theobald, Anke Ohler, Irene Schmidtmann, Georg Hess, Peter Dreger
DOI: 10.1038/s41409-025-02789-7
Cited by: 2
References: 11

Abstract

Mantle Cell Lymphoma (MCL) is an incurable B-cell neoplasm, representing 6–8% of newly diagnosed B-cell lymphomas [ 1 ]. Brexucabtagene-autoleucel (brexu-cel, Tecartus®) is a CD19-targeting chimeric antigen receptor (CAR) T-cell therapy approved in Europe for treatment of relapsed/refractory (r/r) MCL after two prior lines of therapy, including a Bruton’s tyrosine kinase inhibitor (BTKi) [ 2 ]. Approval was based on a small population of 68 patients in the ZUMA-2 trial [ 2 ]. Therefore, data on toxicities and long-term outcomes in a real-world setting are of great value to confirm the potential and show limitations of brexu-cel.

Fields of Study & Subjects

Lymphoma Diagnosis and Treatment CAR-T cell therapy research T-cell and Retrovirus Studies

Publication details

Journal / source
Bone Marrow Transplantation
Publisher
Springer Science and Business Media LLC
Volume
61
Issue
4
Pages
480–483
Publication date
16 January 2026
Language
EN